期刊
ONCOGENE
卷 35, 期 20, 页码 2562-2564出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2015.392
关键词
-
资金
- Department of Health [NIHR-RP-011-053] Funding Source: Medline
- Cancer Research UK [14549] Funding Source: researchfish
- National Institute for Health Research [NIHR-RP-011-053] Funding Source: researchfish
Recent clinical research has provided evidence that cancer progression and therapy resistance is driven not only by tumor's genetic profile but also by complex paracrine interactions within the tumor microenvironment (TME). The role of TME in modulating tumor drug sensitivity is increasingly recognized and targeting TME has been the focus of novel therapeutic approaches. Two recent reports show that a new anti-cancer drug, the inhibitor NT157 has the potential to inhibit IGF-1R and STAT3 signaling pathways in cancer cells and stroma cells of TME leading to a decrease in cancer cell survival.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据